ArticleAdvances in therapy2026
A Real-World Target Trial Emulation of Eteplirsen, Casimersen, and Golodirsen to Evaluate Survival Among Patients with Duchenne Muscular Dystrophy.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionReal-world data are needed to understand the treatment effect of eteplirsen, casimersen, and golodirsen (phosphorodiamidate morpholino oligomers [PMOs]) on all-cause mortality in patients with DMD.
methodsThe study objectives were to describe the unadjusted time to death from treatment start and from birth, assess PMO treatment's impact on survival, and describe the frequency of comorbidities prior to death. Sequential target trial emulation with inverse probability of treatment and censoring weighting were used to compare survival between patients who received glucocorticoids (GCs) and eteplirsen, casimersen, or golodirsen (PMO + GCs) or GCs alone (GCs-only). Inovalon closed claims data (January 2016-September 2024) were tokenized and linked with Datavant mortality data.
resultsIn the PMO + GCs group, 208/372 (56%) received eteplirsen, 123/372 (33%) casimersen, and 41/372 (11%) golodirsen. Twelve of 372 patients (3%) died after treatment initiation with PMO + GCs versus 114/2656 (4%) for GCs-only without adjustment for confounding or length of follow-up. In the adjusted target trial emulation analysis, 112 patients initiated PMOs and 2916 initiated GCs-only treatment in the first trial; median follow-up time was 4.6 and 4.8 years, respectively. In sequential trials, 260/2916 patients originally in the GCs-only group initiated treatment with PMOs. While the mortality rate in both groups was low, data from 48 sequentially emulated trials estimated PMO + GCs reduced mortality risk versus GCs-only (hazard ratio 0.303; 95% confidence interval 0.119-0.769; P = 0.012). In patients from either group with claims in the 3 months preceding death (n = 84), more than 75% had circulatory/respiratory claims.
conclusionThe relative risk reduction in mortality suggests a promising treatment effect of PMO + GCs versus GCs-only, which should be confirmed in future studies with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.